Filtered By:
Cancer: Cancer
This page shows you your search results in order of date. This is page number 15.
Order by Relevance | Date
Total 412620 results found since Jan 2013.
PD-1 blockade induces reactivation of non-productive T cell responses characterized by NF-kB signaling in patients with pancreatic cancer
CONCLUSIONS: Cytotoxic T cells in the blood of PDAC patients remain sensitive to reinvigoration by PD-1 blockade and some have tumor-recognizing potential. Although these T cells proliferate and have a signature of IFN exposure, they also upregulate NF-κB signaling, which potentially counteracts the beneficial effects of anti-PD-1 reinvigoration and marks these T cells as non-productive contributors to anti-tumor immunity.PMID:37733830 | DOI:10.1158/1078-0432.CCR-23-1444
Source: Clinical Cancer Research - September 21, 2023 Category: Cancer & Oncology Authors: Lestat R Ali Patrick J Lenehan Victoire Cardot-Ruffino Andressa Dias Costa Matthew H G Katz Todd W Bauer Jonathan A Nowak Brian M Wolpin Thomas A Abrams Anuj Patel Thomas E Clancy Jiping Wang Joseph D Mancias Matthew J Reilley Chee-Chee H Stucky Tanios S Source Type: research
PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors
CONCLUSIONS: By disrupting an adaptive stress response evoked by VEGFR-TKIs, HC-5404 presents a clinical opportunity to improve the antitumor effects of well-established standard of care therapies in RCC.PMID:37733811 | DOI:10.1158/1078-0432.CCR-23-1182
Source: Clinical Cancer Research - September 21, 2023 Category: Cancer & Oncology Authors: Michael E Stokes Veronica Calvo Sho Fujisawa Crissy Dudgeon Sharon Huang Nupur Ballal Leyi Shen Jennifer Gasparek Matthew Betzenhauser Simon J Taylor Kirk A Staschke Alan C Rigby Mark J Mulvihill Nandita Bose Eric S Lightcap David Surguladze Source Type: research
PD-1 blockade induces reactivation of non-productive T cell responses characterized by NF-kB signaling in patients with pancreatic cancer
CONCLUSIONS: Cytotoxic T cells in the blood of PDAC patients remain sensitive to reinvigoration by PD-1 blockade and some have tumor-recognizing potential. Although these T cells proliferate and have a signature of IFN exposure, they also upregulate NF-κB signaling, which potentially counteracts the beneficial effects of anti-PD-1 reinvigoration and marks these T cells as non-productive contributors to anti-tumor immunity.PMID:37733830 | DOI:10.1158/1078-0432.CCR-23-1444
Source: Cell Research - September 21, 2023 Category: Cytology Authors: Lestat R Ali Patrick J Lenehan Victoire Cardot-Ruffino Andressa Dias Costa Matthew H G Katz Todd W Bauer Jonathan A Nowak Brian M Wolpin Thomas A Abrams Anuj Patel Thomas E Clancy Jiping Wang Joseph D Mancias Matthew J Reilley Chee-Chee H Stucky Tanios S Source Type: research
PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors
CONCLUSIONS: By disrupting an adaptive stress response evoked by VEGFR-TKIs, HC-5404 presents a clinical opportunity to improve the antitumor effects of well-established standard of care therapies in RCC.PMID:37733811 | DOI:10.1158/1078-0432.CCR-23-1182
Source: Cell Research - September 21, 2023 Category: Cytology Authors: Michael E Stokes Veronica Calvo Sho Fujisawa Crissy Dudgeon Sharon Huang Nupur Ballal Leyi Shen Jennifer Gasparek Matthew Betzenhauser Simon J Taylor Kirk A Staschke Alan C Rigby Mark J Mulvihill Nandita Bose Eric S Lightcap David Surguladze Source Type: research
Differential benefit of metronomic chemotherapy among triple negative breast cancer subtypes treated in the IBCSG Trial 22-00
CONCLUSIONS: Our results show a differential benefit of low-dose CM therapy across different TNBC subtypes. Low-dose CM therapy could be considered as a potential immunomodulatory strategy for TNBC tumors with IM subtype in the early-disease setting.PMID:37733800 | DOI:10.1158/1078-0432.CCR-23-1267
Source: Cell Research - September 21, 2023 Category: Cytology Authors: Andrea Joaquin Garcia Mattia Rediti David Venet Samira Majjaj Roswitha Kammler Elisabetta Munzone Lorenzo Gianni Beat Th ürlimann Istv án Láng Marco Colleoni Sherene Loi Giuseppe Viale Meredith M Regan Laurence Buisseret Fran çoise Rothé Christos Sot Source Type: research
ATM mutations associate with distinct co-mutational patterns and therapeutic vulnerabilities in NSCLC
CONCLUSIONS: ATM mutations define a distinct subset of NSCLC associated with KRAS mutations, increased TMB, decreased TP53 and EGFR co-occurrence, and potential increased sensitivity to ICIs in the context of DNA-damaging chemotherapy.PMID:37733794 | DOI:10.1158/1078-0432.CCR-23-1122
Source: Cell Research - September 21, 2023 Category: Cytology Authors: Natalie I Vokes Ana Galan Cobo Margarita Fernandez-Chas David Molkentine Santiago Trevi ño Vitaly Druker Yu Qian Sonia Patel Stephanie Schmidt Lingzhi Hong Jeff Lewis Waree Rinsurongkawong Vadeerat Rinsurongkawong J Jack Lee Marcelo V Negrao Don L Gibbon Source Type: research
Personalized Medicine's Coming of Age: One Drug, One Patient
Clin Cancer Res. 2023 Sep 21. doi: 10.1158/1078-0432.CCR-23-2194. Online ahead of print.ABSTRACTA dendritic cell/myeloma fusion vaccine, given with lenalidomide and GM-CSF, did not result in a statistically significant increase in CR rates at 1-year post-transplant but was associated with a significant increase in circulating multiple myeloma-reactive lymphocytes indicative of tumor-specific immunity.PMID:37733765 | DOI:10.1158/1078-0432.CCR-23-2194
Source: Cell Research - September 21, 2023 Category: Cytology Authors: Muzaffar H Qazilbash Larry W Kwak Source Type: research
Identification of a TRP channel-related risk model for predicting prognosis and therapeutic effects of patients with hepatocellular carcinoma
CONCLUSIONS: We successfully established a highly accurate prognostic model for predicting overall survival and therapeutic effects using TRP channel-related genes.PMID:37733242 | DOI:10.1007/s00432-023-05394-7
Source: Cell Research - September 21, 2023 Category: Cytology Authors: Chong Pang Zhe Xu Jilong Han Fujun Li Hongyan Zhu Jiaqi Zhang Dong Wang Xundi Xu Source Type: research
Integrated analysis of tumor microenvironment features to establish a diagnostic model for papillary thyroid cancer using bulk and single-cell RNA sequencing technology
CONCLUSIONS: Our study comprehensively characterized the tumor microenvironment in papillary thyroid cancer. Through combined analysis with bulk RNA-seq, six potential diagnostic biomarkers were identified and validated. The diagnostic model we constructed was a promising tool for PTC diagnosis. Our findings provide new insights into the heterogeneity of thyroid cancer and the theoretical basis for diagnosing thyroid cancer.PMID:37733241 | DOI:10.1007/s00432-023-05420-8
Source: Cell Research - September 21, 2023 Category: Cytology Authors: Yizeng Wang Wenbin Song Yingxi Li Zhaoyi Liu Ke Zhao Lanning Jia Xiaoning Wang Ruoyu Jiang Yao Tian Xianghui He Source Type: research
CD4 levels and NSCLC metastasis: the benefits of maintaining moderate levels
CONCLUSIONS: A threshold effect is shown to exist between the peripheral blood CD4 and distant metastasis in NSCLC patients. It was revealed that the risk of distant metastasis is lower when CD4 is maintained between 32 and 44%, whereas low (< 32%) or high (> 44) levels of CD4 are associated with an increased risk of distant metastasis in NSCLC patients.PMID:37733240 | DOI:10.1007/s00432-023-05418-2
Source: Cell Research - September 21, 2023 Category: Cytology Authors: Ying Bai Yafeng Liu Jing Wu Rui Miao Zhi Xu Chunxiao Hu Jiawei Zhou Jianqiang Guo Jun Xie Zilun Shi Xuansheng Ding Yingru Xing Dong Hu Source Type: research
Baseline interleukin-6 is a prognostic factor for patients with metastatic breast cancer treated with eribulin
CONCLUSION: Baseline IL-6 is an important prognostic factor in patients with MBC treated with eribulin. Our results show that high IL-6 is associated with higher levels of MDSCs which suppress anti-tumor immunity, such as CD8+ cells. It appears that eribulin is not particularly effective in patients with high IL-6 due to a poor tumor immune microenvironment.PMID:37733188 | DOI:10.1007/s10549-023-07086-9
Source: Cell Research - September 21, 2023 Category: Cytology Authors: Ayako Bun Masayuki Nagahashi Mamiko Kuroiwa Miki Komatsu Yasuo Miyoshi Source Type: research
Eribulin promotes proliferation of CD8 < sup > + < /sup > T cells and potentiates T cell-mediated anti-tumor activity against triple-negative breast cancer cells
CONCLUSIONS: Eribulin promoted CD8+ T cell proliferation, repressed effector T cell differentiation, and harnessed T cell-mediated anti-tumor effects. These mechanisms may be one of the cues that eribulin can improve the immunological status of tumor-bearing hosts.PMID:37733186 | DOI:10.1007/s10549-023-07111-x
Source: Cell Research - September 21, 2023 Category: Cytology Authors: Tadafumi Shimizu Takaaki Oba Masanori Oshi Ken-Ichi Ito Source Type: research
Diverse functions of myeloid-derived suppressor cells in autoimmune diseases
Immunol Res. 2023 Sep 21. doi: 10.1007/s12026-023-09421-0. Online ahead of print.ABSTRACTSince myeloid-derived suppressor cells (MDSCs) were found suppressing immune responses in cancer and other pathological conditions, subsequent researchers have pinned their hopes on the suppressive function against immune damage in autoimmune diseases. However, recent studies have found key distinctions of MDSC immune effects in cancer and autoimmunity. These include not only suppression and immune tolerance, but MDSCs also possess pro-inflammatory effects and exacerbate immune disorders during autoimmunity, while promoting T cell prol...
Source: Cell Research - September 21, 2023 Category: Cytology Authors: Xin Xiong Yang Zhang Yu Wen Source Type: research
Piperacetazine directly binds to the PAX3::FOXO1 fusion protein and inhibits its transcriptional activity
Cancer Res Commun. 2023 Sep 21. doi: 10.1158/2767-9764.CRC-23-0119. Online ahead of print.ABSTRACTThe tumor-specific chromosomal translocation product, PAX3::FOXO1, is an aberrant fusion protein that plays a key role for oncogenesis in the alveolar subtype of rhabdomyosarcoma (RMS). PAX3::FOXO1 represents a validated molecular target for alveolar RMS and successful inhibition of its oncogenic activity is likely to have significant clinical applications. Even though several PAX3::FOXO1 function-based screening studies have been successfully completed, a directly binding small molecule inhibitor of PAX3::FOXO1 has not been r...
Source: Cell Research - September 21, 2023 Category: Cytology Authors: Kay Nakazawa Taryn Shaw Young K Song Marilyn Kouassi-Brou Anna Molotkova Purushottam B Tiwari Hsien-Chao Chou Xinyu Wen Jun S Wei Emre Deniz Jeffrey Toretsky Charles Keller Frederic G Barr Javed Khan Aykut Üren Source Type: research
Chromatin accessibility landscape of human triple-negative breast cancer cell lines reveals variation by patient donor ancestry
Cancer Res Commun. 2023 Sep 21. doi: 10.1158/2767-9764.CRC-23-0236. Online ahead of print.ABSTRACTAfrican American (AA) women have an excessive risk of developing triple-negative breast cancer (TNBC). We employed ATAC-sequencing to characterize differences in chromatin accessibility between 9 commonly used TNBC cell lines derived from patients of European and African ancestry. Principal component and chromosome mapping analyses of accessibility peaks with the most variance revealed separation of chromatin profiles by patient group. Motif enrichment and footprinting analyses of disparate open chromatin regions revealed diff...
Source: Cell Research - September 21, 2023 Category: Cytology Authors: Alexandra R Harris Gatikrushna Panigrahi Huaitian Liu Vishal N Koparde Maeve Bailey-Whyte Tiffany H Dorsey Clayton C Yates Stefan Ambs Source Type: research
